HIV vaccine / Gilead, Nexoplex bio - LARVOL DELTA

Comparing CD8+ T cell ENV epitopes of two HLA class I alleles associated with different outcomes of HIV-1 infection with broadly neutralizing antibodies epitope targets discovered to date. (PubMed, Front Immunol) - "The HIV vaccine field has swung between humoral-based to cell-mediated approaches; however the consensus has evolved toward the understanding that an induction of both may be important for optimal protection...Notably, all A*01:01 T cell epitopes overlapping bNAb epitopes were within conserved ENV regions, and all but one involved glycan-dependent bNAb binding. The epitope landscape analysis therefore showed the allele associated with slower HIV-1 infection rates presents a narrower repertoire of ENV CD8+ T cell epitopes, that preferentially overlaps bNAb target sites, consistent with coordinated immune targeting between cellular and humoral arms of immunity."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist. (PubMed, J Immunol) - "While therapeutic vaccines are a promising strategy for inducing human immunodeficiency virus (HIV) control, HIV vaccines tested to date have offered limited benefit to people living with HIV...Combination with FLT3Ra also expanded polyfunctional CD4+ T cell responses. Our data demonstrate enhanced and distinct shaping of vaccine-elicited immune responses by immune modulators with implications for developing a functional HIV cure."

Journal • Human Immunodeficiency Virus • Infectious Disease • Oncology • CD4

"$grts working on HIV vaccine with @GileadSciences" (,@SurvivingCrypto)

Clinical • Human Immunodeficiency Virus • Infectious Disease

[VIRTUAL] A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION (CROI 2021) - P1, P2a | "Background: HTI is a novel HIV vaccine immunogen designed at redirecting cellular immune responses to HIV targets associated with viral control. The AELIX-002 trial (NCT03204617) was a randomized, singlecenter, placebo-controlled trial to evaluate the safety, immunogenicity and antiviral effect of DNA.HTI (D), MVA.HTI (M) and ChAdOx1.HTI (C) vaccines after discontinuation of ART in early-treated people living with HIV (PLWH)... HTI vaccines were safe and highly immunogenic in early-treated PLWH with a prolonged time off ART seen in vaccinees with non-beneficial HLA class I alleles. Time off ART positively correlated with vaccine-induced HTIspecific T cell responses at ATI start. Multivariate analysis for other correlates of response is ongoing."

Clinical • Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease • CD4

"Wake up n smell the coffee the industry doesn't want an HIV vaccine the drug industry is too profitable it would put Gilead out of business who owns @GileadSciences the former FDA commissioner Hamburg w her husband 5%via Renaissance capital Fauci's vaccine failed it's his way" (,@ImmuneResponseB)

Human Immunodeficiency Virus • Infectious Disease